Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Heather M. Moore(Biomarker Technologies (China)), Timothy R. Wilson, Mark R. Lackner(Zen-Noh (Japan)), Carol O’Brien(Trinity College Dublin), Ciara Metcalfe(Gene Therapy Laboratory), Ethan S. Sokol(Foundation Medicine (United States)), Lori S. Friedman, Heidi Savage(Biomarker Technologies (China)), Wei Zhou(Broad Institute), Michael E. Goldberg(University of Utah)
Cited by 10
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Identification of common variants associated with human hippocampal and intracranial volumes
|Nature Genetics|2012|662
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255